A recent observational study conducted by Simrén and colleagues investigated both the diagnostic and prognostic capabilities of the following plasma biomarkers of AD pathology: plasma total β-amyloid (Aβ), the 40- and 42-amino acid forms of β-amyloid (Aβ42/Aβ40) ratio, T-tau, P-tau181, axonal injury (neurofilament light; NfL), and astrogliosis (glial fibrillary acidic protein; GFAp) [59]. The gene discussed is NEFL; the disease is Alzheimer disease.